Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 2.54% and Operating profit at 0.74% over the last 5 years
3
Flat results in Jun 25
4
With ROE of 6.67%, it has a very attractive valuation with a 0.87 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 43,686 Million (Small Cap)
13.00
NA
0.00%
-0.49
6.70%
0.98
Revenue and Profits:
Net Sales:
5,890 Million
(Quarterly Results - Jun 2025)
Net Profit:
392 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.23%
0%
4.23%
6 Months
13.4%
0%
13.4%
1 Year
1.5%
0%
1.5%
2 Years
4.07%
0%
4.07%
3 Years
10.53%
0%
10.53%
4 Years
1.58%
0%
1.58%
5 Years
-10.0%
0%
-10.0%
Medikit Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.54%
EBIT Growth (5y)
0.74%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0.49
Tax Ratio
35.33%
Dividend Payout Ratio
44.00%
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
24.12%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.87
EV to EBIT
3.65
EV to EBITDA
2.65
EV to Capital Employed
0.74
EV to Sales
0.73
PEG Ratio
1.06
Dividend Yield
NA
ROCE (Latest)
20.30%
ROE (Latest)
6.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
5,890.00
5,628.30
4.65%
Operating Profit (PBDIT) excl Other Income
1,444.80
1,446.60
-0.12%
Interest
1.90
0.00
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
392.20
405.50
-3.28%
Operating Profit Margin (Excl OI)
173.60%
191.60%
-1.80%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.65% vs 1.41% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -3.28% vs -28.14% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
22,553.20
21,850.50
3.22%
Operating Profit (PBDIT) excl Other Income
6,175.10
6,218.50
-0.70%
Interest
0.00
0.00
Exceptional Items
-0.10
74.10
-100.13%
Consolidate Net Profit
3,013.50
3,069.50
-1.82%
Operating Profit Margin (Excl OI)
198.90%
213.90%
-1.50%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 3.22% vs 1.13% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -1.82% vs 7.15% in Mar 2024
About Medikit Co., Ltd. 
Medikit Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






